Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?

Zacks12-23 21:03

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493635807?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Ow0iDerAjZpVuDySWQKxLQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/97cc056941ceefa188b6de00cd4eeb99","is_english":true,"pubTime":"2024-12-23 21:03","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493635807","market":"us","top_or_hot":-1,"title":"Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?","media":"Zacks","content":"<div>\n<p>Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-stock-down-39-three-130300706.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Stock Down 39% in Three Months: Buy the Dip or Wait?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 21:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-stock-down-39-three-130300706.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-stock-down-39-three-130300706.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1061106388.HKD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-stock-down-39-three-130300706.html","article_id":"2493635807","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Ow0iDerAjZpVuDySWQKxLQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/97cc056941ceefa188b6de00cd4eeb99"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493635807","pubTimestamp":1734958980,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the vaccine.In the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well with investors. During this timeframe, the stock has also underperformed the broader Medical sector and the S&P 500. Shares of Moderna are currently trading below its 200-day and 50-day moving averages.MRNA Stock Underperforms Industry, Sector & S&P 500. We are also encouraged by the company’s plans to launch 10 new marketed products over the next three years. Moderna plans to submit three regulatory filings seeking th","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","BK4501":"段永平概念","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4588":"碎股","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","PFE":"辉瑞","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","MRK":"默沙东","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","BNTX":"BioNTech SE","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0238689110.USD":"贝莱德环球动力股票基金","BK4516":"特朗普概念","BK4532":"文艺复兴科技持仓","BK4592":"伊斯兰概念","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","MRNA":"Moderna, Inc.","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4007":"制药","GSK.UK":"葛兰素史克","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","GSK":"葛兰素史克","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC"},"translate_title":"Moderna股价三个月内下跌39%：逢低买入还是等待？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"MRK":1,"GSK":1,"MRNA":0.9,"BNTX":0.9,"GSK.UK":0.6},"content_text":"Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the vaccine.\nIn the past three months, MRNA stock has lost nearly 40%, significantly underperforming the industry’s 17.1% decline, as seen in the chart below. While the company’s pipeline progress has been encouraging, the update to its business outlook for the next four years and a curtailed R&D budget did not sit well with investors. During this timeframe, the stock has also underperformed the broader Medical sector and the S&P 500. Shares of Moderna are currently trading below its 200-day and 50-day moving averages.\nMRNA Stock Underperforms Industry, Sector & S&P 500\n Image Source: Zacks Investment Research\nAdding to these challenges is the major downturn in the broader drug/biotech sector due to lower-than-expected third-quarter results, guidance cuts and pipeline setbacks. Last month, President-elect Donald Trump announced his decision to nominate vaccine skeptic Robert F. Kennedy Jr. to run the Department of Health and Human Services. These factors have negatively impacted nearly all companies in the sector.\nModerna’s Revised Business Outlook\nIn September, management issued fresh sales guidance for full year 2025 and also revised the previously issued sales outlook for 2028.\nModerna expects to generate revenues between $2.5 billion and $3.5 billion in 2025. For 2026-2028, management expects sales to witness a CAGR of more than 25%, driven by new product launches. This revised long-term outlook was much lower than that announced last year. Management had previously expected to generate an additional $10-$15 billion in annual sales from cancer, rare and latent disease therapies by 2028.\nAlongside the guidance cut, Moderna also implemented a portfolio prioritization and cost efficiency program to reduce annual R&D expenses and focus on products that are either nearing approval or already in the market. The company reduced its overall R&D budget for the next four years (2025 to 2028) by nearly 20% to $16 billion. Management decided to discontinue five pipeline programs as part of this prioritization program.\nBased on this revised outlook, Moderna now expects to break even on an operating cash cost basis in 2028, two years later than the previously announced goal of 2026.\nModerna’s Plans for Product Launches\nThe FDA approval of mRNA-based RSV vaccine mResvia in May was a milestone for Moderna as it marks the first product approval outside the COVID-19 vaccine space. Though this vaccine only generated a modest sales figure of $10 million in third-quarter 2024, we remain confident about the sales potential of the vaccine in the long term despite competition from rivals GSK plc GSK and Pfizer PFE.\nWe are also encouraged by the company’s plans to launch 10 new marketed products over the next three years. Moderna plans to submit three regulatory filings seeking the FDA’s approval. This includes fresh regulatory filings for mRNA-1283 (next-generation COVID-19 vaccine) and mRNA-1083 (COVID-19 plus and influenza combination vaccine). Moderna also plans to file a regulatory filing for mResvia seeking label expansion for use in high-risk adults aged 18-59.\nWith these potential launches, management aims to boost the company’s revenues and reduce its dependence on the COVID-19 vaccine, which has been experiencing a significant decline due to lower vaccinations with the end of the pandemic.\nMRNA’s Progress With Pipeline\nThe company is also progressing well with the development of its pipeline candidates. Unlike traditional vaccines that can take months to produce, mRNA-based vaccines can be developed quickly and offer manufacturing scalability, which was observed in the case of COVID-19 vaccines. Because of this major advantage, Moderna received a project award of $176 million from the U.S. government to accelerate the development of an mRNA-based vaccine program to prevent the spread of the H5N1 virus, also known as bird flu, in humans.\nAn important candidate that has been garnering investors’ attention is mRNA-4157, an investigational individualized neoantigen therapy (INT) being developed in collaboration with Merck MRK. Moderna/Merck are evaluating mRNA-4157 in in three pivotal phase III studies — one in melanoma indication and the other two in the non-small cell lung cancer (NSCLC) area. Since the onset of this year, Moderna/Merck initiated three mid-stage studies in cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma and muscle-invasive bladder cancer indications.\nApart from mRNA-4157, Moderna is also evaluating multiple vaccine candidates in late-stage studies, including CMV, influenza and norovirus. Data from the CMV study is expected as early as 2024-end. Overall, management is evaluating more than 40 mRNA-based investigational candidates in its pipeline across different stages of clinical development.\nMRNA Stock’s Valuation & Estimates\nFrom a valuation standpoint, Moderna appears attractive compared to the industry. Going by the price/sales (P/S) ratio, the company’s shares currently trade at 3.09, trailing 12-month sales value, lower than 6.61 for the industry.\n Image Source: Zacks Investment Research\nEstimates for Moderna’s 2024 loss per share have improved from $9.94 to $9.30 in the past 60 days.During this timeframe, estimates for 2025 loss per share have increased from $8.59 to $8.85.\n Image Source: Zacks Investment Research\nStay Invested in MRNA Stock\nModerna’s upcoming product launches should help the company diversify its revenue stream, which is majorly dependent on the COVID-19 vaccine for revenues. While we acknowledge that Moderna faces stiff competition in target markets from pharma giants like Pfizer and GSK, we recommend investors to accumulate this Rank #3 (Hold) stock as it has growth potential based on the strong cash balance and robust pipeline progress.\nWe are encouraged by management’s progress with the development of its COVID-19-influenza combination vaccine, which could be a major game-changer for the stock. While rivals like Pfizer, Sanofi and Novavax are also developing similar combination vaccines, Moderna currently remains ahead in terms of clinical development.\nInvestors should also look for updates on the company’s pipeline candidates, which could also be catalysts for the stock. If the data from the CMV study is positive, we could expect updates from the company on its launch plans for the vaccine. Currently, there is no approved CMV vaccine in the United States.\nYou can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nGSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nMerck & Co., Inc. (MRK) : Free Stock Analysis Report\nModerna, Inc. (MRNA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493635807"}